Sirnaomic Mediaroom - PR Newswire APAC

Sirnaomics Announces a Partnership with Gore Range Capital for Establishment of a JV, Sagesse Bio, to Advance Its RNAi Therapeutics into Aesthetic Medicine

HONG KONG, GERMANTOWN, Md. and SUZHOU, China, Aug. 1, 2024 /PRNewswire/ -- Sirnaomics Ltd.(the "Com...

2024-08-01 11:26 1866

Sirnaomics Announces Completion of IND-Enabling Studies of Safety and Efficacy for STP125G with NHP Models, Targeting ApoC3 for Treatment of Cardiovascular Diseases

HONG KONG, GERMANTOWN, Md. and SUZHOU, China, July 12, 2024 /PRNewswire/ -- Sirnaomics Ltd.(the "Co...

2024-07-12 16:53 4132

Sirnaomics Announces Interim Results for Successful Completion of the Second Cohort of Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Therapeutics

HONG KONG and GERMANTOWN, Md. and SUZHOU, China, July 8, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the ...

2024-07-08 14:30 2001

Sirnaomics Announces Completion of STP707 Phase I Clinical Study with Strong Safety Profile and Disease Activity for the Treatment of Pancreatic Cancer Patients

HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 28, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "C...

2024-06-28 13:44 2242

Sirnaomics Demonstrates Strong Antitumor Activity of Its Novel Oligonucleotide-ChemoDrug Conjugate in Journal of Oncology Research and Therapy

HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 13, 2024 /PRNewswire/ -- Sirnaomics Ltd.(the "Co...

2024-06-13 18:03 2613

Sirnaomics Announces 2023 Annual Results

Focuses on the Consolidation for Leading Projects Accelerates Clinical Trials for Core Products ST...

2024-03-28 17:09 4347

Sirnaomics Publishes Novel Mechanism of Action of RNAi Cancer Therapeutic STP707 for Solid Tumors

Study published in NAR Cancer, a leading peer-reviewed journal in the field of nucleic acid therape...

2024-01-24 17:49 1812

RNAimmune Receives Investigational New Drug Application Clearance from U.S. FDA for mRNA-Based Respiratory Syncytial Virus Vaccine RV-1770

GERMANTOWN, Md and GUANGZHOU, China, Dec. 18, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", ...

2023-12-18 22:04 2267

Sirnaomics Announces Successful Completion of Cohort 1 from Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment

HONG KONG and GERMANTOWN, Md. and SUZHOU BIOBAY, China, Dec. 6, 2023 /PRNewswire/ --Sirnaomics Ltd....

2023-12-06 01:01 2098

Sirnaomics Promotes Francois Lebel, M.D. to Chief Medical Officer

HONG KONG, Germantown, Md. and Suzhou, China, Dec. 1, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Co...

2023-12-01 14:41 2030

Sirnaomics Presents Positive Clinical Data of STP705 for Focal Fat Reduction

The Group is Advancing the Program to a Phase II Clinical Study Data presented at the 2023 Fall Cli...

2023-11-01 22:07 2065

Sirnaomics Announces Successful Phase I Clinical Study of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors

* Six cohorts, totaling 50 late-stage cancer patients, received STP707 four times monthly by intr...

2023-08-31 11:30 4562

Sirnaomics Announces 2023 Interim Results

Positive Clinical Readouts Validate Potential of Proprietary Delivery Platforms and Cement Global L...

2023-08-31 10:40 4204

Sirnaomics Appoints Dr. Francois Lebel as Senior Vice President for Preclinical and Clinical Development

HONG KONG, Germantown, Md. and SUZHOU, China, July 28, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "C...

2023-07-28 11:56 2204

Sirnaomics to Present Latest Developments on Two Proprietary Delivery Platforms at Upcoming Industry Conferences

HONG KONG, Germantown, Md. and SUZHOU, China, July 12, 2023 /PRNewswire/ -- Sirnaomics Ltd.(the "Co...

2023-07-12 20:45 2621

Sirnaomics Establishes a Strategic Partnership with EDIRNA Inc., an RNA-Editing Therapeutic Company

HONG KONG and GERMANTOWN, Md. and SUZHOU BIOBAY, China, July 5, 2023 /PRNewswire/ --Sirnaomics Ltd....

2023-07-05 23:07 2564

Sirnaomics Advances STP705 for Squamous Cell Carcinoma In Situ into Late-Stage Clinical Development

HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 19, 2023 /PRNewswire/ -- Sirnaomics Ltd.(the "Co...

2023-06-19 21:29 3949

Sirnaomics to Present Latest Developments on GalAhead™ Therapeutic Platform at Upcoming Industry Conferences

HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 14, 2023 /PRNewswire/ -- Sirnaomics Ltd.(the "Co...

2023-06-14 00:42 2649

Sirnaomics Reports Interim Results of STP705 Phase I Clinical Study for Medical Aesthetics Treatment in Adults Undergoing Abdominoplasty

HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 5, 2023 /PRNewswire/ -- Sirnaomics Ltd.(the "Com...

2023-06-05 19:12 2960

Sirnaomics Dosed the First Patient in Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment

HONG KONG, Germantown, Md. and Suzhou, China, June 2, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Co...

2023-06-02 00:06 6925

Latest News